Chardan Capital Maintains Buy on Gain Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Gain Therapeutics (NASDAQ:GANX) and keeps the price target at $6.
August 09, 2024 | 9:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae maintains a Buy rating on Gain Therapeutics (NASDAQ:GANX) and keeps the price target at $6.
The reaffirmation of a Buy rating and a $6 price target by Chardan Capital is likely to positively impact the short-term stock price of Gain Therapeutics. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100